GlassScriptPhysician profile
Patrick F Mathias
NPI 1982604989
$5,672.21
in general payments reported to CMS, 2019-2025
35 companies · $1,010 in 2025
The $1,010 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $701 · 2020: $494 · 2021: $827 · 2022: $1,073 · 2023: $691 · 2024: $878 · 2025: $1,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,437 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,437.10 |
| Education | $141.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $532.36 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $449.92 | 2019-2025 | |
| Abiomed | $439.57 | 2019-2025 | Impella |
| Astrazeneca Pharmaceuticals LP | $424.02 | 2020-2025 | Farxiga, Brilinta |
| Alnylam Pharmaceuticals INC. | $403.10 | 2022-2025 | Onpattro |
| Merck Sharp & Dohme LLC | $325.95 | 2022-2025 | Verquvo, Capvaxive |
| Abbott Laboratories | $291.03 | 2019-2022 | |
| Amarin Pharma, INC. | $261.21 | 2019-2022 | |
| Astellas Pharma US INC | $261.00 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.16 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $190.78 | 2019-2025 | |
| Cvrx, INC. | $161.82 | 2022-2025 | Barostim Neo System |
| Amgen INC. | $161.74 | 2022-2024 | Repatha |
| Actelion Pharmaceuticals US, INC. | $145.67 | 2021-2022 | |
| Medtronic, INC. | $143.68 | 2021-2025 | Symplicity G3, Resolute Onyx |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $134.06 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $132.72 | 2019-2025 | Camzyos, Eliquis |
| Kowa Pharmaceuticals America, INC. | $128.67 | 2019-2021 | |
| Esperion Therapeutics, INC. | $121.13 | 2021-2025 | Nexletol |
| Atricure, INC. | $92.00 | 2023-2025 | Synergy Ablation System |
| Pfizer INC. | $89.27 | 2019-2025 | |
| Novo Nordisk INC | $84.49 | 2020-2025 | Wegovy, Ozempic |
| Sanofi-Aventis U.S. LLC | $83.53 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $82.29 | 2019-2025 | Lifevest |
| Kestra Medical Technology Services, INC. | $74.13 | 2024-2025 | Assure Wcd |
| Kiniksa Pharmaceuticals, LTD. | $53.94 | 2023 | Arcalyst |
| Medtronic Vascular, INC. | $46.84 | 2019-2020 | |
| Impulse Dynamics (USA) INC. | $42.04 | 2022 | |
| Penumbra, INC. | $22.11 | 2025 | Indigo System |
| United Therapeutics Corporation | $17.68 | 2021 | |
| Inspire Medical Systems, INC. | $16.20 | 2025 | Inspire |
| Kiniksa Pharmaceuticals International, Plc | $14.70 | 2024 | Arcalyst |
| Medicure Pharma INC. | $12.50 | 2022 | |
| Daiichi Sankyo INC. | $12.11 | 2019 | |
| Biotronik INC. | $11.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Mathias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.